Clinical characteristics of hypersensitivity pneumonitis: non-fibrotic and fibrotic subtypes

• Published in: Chinese medical journal Vol. 136; no. 23; pp. 2839 - 2846
• Main Authors: Chen, Xueying, Yang, Xiaoyan, Ren, Yanhong, Xie, Bingbing, Xie, Sheng, Zhao, Ling, Wang, Shiyao, Geng, Jing, Jiang, Dingyuan, Luo, Sa, He, Jiarui, Shu, Shi, Hu, Yinan, Zhu, Lili, Li, Zhen, Zhang, Xinran, Liu, Min, Dai, Huaping
• Format: Journal Article
• Language: English
• Published: China Lippincott Williams & Wilkins Ovid Technologies 05.12.2023; Lippincott Williams & Wilkins; Wolters Kluwer
• Subjects: Antigens; Autoimmune diseases; Diaphragm (Anatomy); Disease; Hypothyroidism; Lung transplants; Medical prognosis; Original; Software; Tomography; Variables; Beijing China; China; Japan
• ISSN: 2542-5641; 0366-6999; 2542-5641
• DOI: 10.1097/CM9.0000000000002613

The presence of fibrosis is a criterion for subtype classification in the newly updated hypersensitivity pneumonitis (HP) guidelines. The present study aimed to summarize differences in clinical characteristics and prognosis of non-fibrotic hypersensitivity pneumonitis (NFHP) and fibrotic hypersensitivity pneumonitis (FHP) and explore factors associated with the presence of fibrosis. In this prospective cohort study, patients diagnosed with HP through a multidisciplinary discussion were enrolled. Collected data included demographic and clinical characteristics, laboratory findings, and radiologic and histopathological features. Logistic regression analyses were performed to explore factors related to the presence of fibrosis. A total of 202 patients with HP were enrolled, including 87 (43.1%) NFHP patients and 115 (56.9%) FHP patients. Patients with FHP were older and more frequently presented with dyspnea, crackles, and digital clubbing than patients with NFHP. Serum levels of carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 153, gastrin-releasing peptide precursor, squamous cell carcinoma antigen, and antigen cytokeratin 21-1, and count of bronchoalveolar lavage (BAL) eosinophils were higher in the FHP group than in the NFHP group. BAL lymphocytosis was present in both groups, but less pronounced in the FHP group. Multivariate regression analyses revealed that older age, <20% of lymphocyte in BAL, and ≥1.75% of eosinophil in BAL were risk factors for the development of FHP. Twelve patients developed adverse outcomes, with a median survival time of 12.5 months, all of whom had FHP. Older age, <20% of lymphocyte in BAL, and ≥1.75% of eosinophil in BAL were risk factors associated with the development of FHP. Prognosis of patients with NFHP was better than that of patients with FHP. These results may provide insights into the mechanisms of fibrosis in HP.